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SBackground: Video-assisted thoracic surgical (VATS) lobectomies and wedge resections result in less
morbidity and shorter length of stay than resections via thoracotomy. The impact of robot-assisted thoracic
surgical (RATS) lobectomy on clinical and economic outcomes has not been examined. This study compared
hospital costs and clinical outcomes for VATS lobectomies and wedge resections versus RATS.
Methods: Using the Premier hospital database, patients aged 18 years with a record of thoracoscopic
lobectomy, segmental resection, or excision of a lesion or tissue from the lung between 2009 and 2011 were
identified. Procedures using robotic technology were identified if 1 of 2 conditions were met: (1) a robotic
International Classification of Diseases, Ninth Revision procedure code or (2) the text fields in the hospital
record indicated that the robot was used. Using a propensity score and based on severity and comorbidities,
certain demographics and hospital characteristics were matched. The association between VATS or RATS
and adverse events, hospital costs, surgery time, and length of stay was examined.
Results: Of 15,502 patient records analyzed, 96% (n ¼ 14,837) were performed without robotic assistance.
Using robotic assistance was associated with higher average hospital costs per patient. The average cost of
inpatient procedures with RATS was $25,040.70 versus $20,476.60 for VATS (P ¼ .0001) for lobectomies
and $19,592.40 versus $16,600.10 (P ¼ .0001) for wedge resections, respectively. Inpatient operating times
were longer for RATS lobectomy than VATS lobectomy (4.49 hours vs 4.23 hours; P ¼ .0959) and wedge
resection (3.26 vs 2.86 hours; P ¼ .0003). Length of stay was similar with no differences in adverse events.
Conclusions: RATS lobectomy and wedge resection seem to have higher hospital costs and longer operating
times, without any differences in adverse events. (J Thorac Cardiovasc Surg 2014;147:929-37)e Division of Minimally Invasive Thoracic Surgery,a Brigham and Women’s
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The Journal of Thoracic and CaLung surgery for the purpose of diagnosis or treatment has
evolved in the past 2 decades. Historically, surgery
involving the lung was accomplished using 1 of 2 main
approaches, depending on the clinical indication: via a
thoracoscope inserted using a small incision or by an
open thoracotomy, involving a larger incision and rib
spreading to improve visibility and access for control of
the surgical anatomy.
Thoracoscopic procedures have been transformed by the
ongoing refinement of video-assisted thoracoscopic
surgery (VATS) techniques and equipment, particularly
high-definition cameras and monitors. For traditional
thoracotomy indications, VATS is an evolving technique
and is increasingly applied in situations where traditional
open thoracotomy has long been used. There is a small
but increasing literature to support the growth of VATS in
this context. However, VATS is still an evolving phenome-
non, with a developing research base,1-4 and with a variable
definition.3-5 Variations exist in the number of port incisions
and the appropriate incision length.
The purported benefits of VATS in lung surgery
compared with open thoracotomy in the literaturerdiovascular Surgery c Volume 147, Number 3 929
TABLE 1. Attrition
Description
Number of
patients
remaining
Number of
patients
dropped
for this reason
Total number of patients in
Premier database 2009
Q1 to 2011 Q2
102,914,774
Patients with a primary
procedure code for
lobectomy or wedge
resection (32.20, 32.30, 32.41)
15,965 102,898,809
Patients 18 y or older at date of
procedure
15,596 369
Patients with inpatient visits only 15,502 94
Abbreviations and Acronyms
APR-
DRG
¼ All Patient Refined Diagnosis Related
Groups
ICD-9 ¼ International Classification of Diseases,
Ninth Edition
RATS ¼ robot-assisted thoracic surgical
SD ¼ standard deviation
VATS ¼ video-assisted thoracic surgical
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Spublished to date includes smaller incisions, less pain, less
blood loss, less respiratory compromise, less complica-
tions, and faster recovery times, all translating into shorter
length of stay and similar survival.6 These findings have
been reported in systematic reviews of randomized and
nonrandomized clinical trials,7 and in comparative
studies.2 In a comparative study of patients with lung can-
cer, Cajipe and colleagues,8 found that there were fewer
complications in VATS patients (14 of 46, 30%) than their
open counterparts (26 of 45, 58%; P ¼ .009). VATS pa-
tients also had a chest tube for a shorter time and shorter
length of stay. In multivariate analysis, VATS was associ-
ated independently with a reduced risk of complications
(odds ratio, 0.359; P ¼ .04).
The impact of RATS on clinical and economic outcomes
has not been examined, however. This study compared
hospital costs and clinical outcomes for VATS lung
resection versus RATS lung resection.
Despite several publications in support of robotic
surgery, controversy still remains over limited high-
quality evidence of improved clinical outcomes compared
with traditional minimally invasive approaches. Clinical
outcomes suggest that robotic surgery is equivalent to con-
ventional minimally invasive procedures when important
end points such as conversion to open surgery, hospital
stay, and recovery time are considered.9,10
The adoption and diffusion of this technology in thoracic
surgery, coupled with limited high-quality evidence of
improved outcomes compared with traditional VATS
procedures, raises important questions about resource
allocation. The systems typically cost between $1 million
and $2.5 million11 plus an additional expensive yearly
service contract. Additional direct costs of robotic-
assisted surgery include instrument disposables and
potentially increased procedure time.
In this era of comparative effectiveness and health care
reform in the United States, and with concerns about
resource utilization at the forefront, the trend toward
RATS deserves further evaluation. Therefore, this study
examined the clinical and economic outcomes (cost and
utilization) in patients undergoing VATS lung resection
versus RATS lung resection.930 The Journal of Thoracic and Cardiovascular SurgMATERIALS AND METHODS
Data Source
The Premier hospital database was used as the data source for this
study.12 This database contains complete data on patient billing, hospital
costs, and coding histories from more than 600 health care facilities
throughout the United States. The data for this study were extracted from
more than 25 million inpatient discharges and 175 million hospital
outpatient visits from acute care facilities, ambulatory surgery centers,
and clinics across the nation.
A protocol describing the analysis objectives, criteria for patient
selection, data elements of interest, and statistical methods was submitted
to the New England Institutional Review Board (NEIRB) and exemption
was obtained.
Eligible patients were 8 years of age and had undergone a VATS
lobectomy or wedge resection between 2009 and 2011, for which the
lobectomy or wedge resection was the primary reason for surgery.
Patients were categorized according to the following types of VATS
procedure: lobectomy (code 32.41), wedge resection (code 32.30 or 32.20).
Lobectomy and wedge resection procedures using robotic technology
were identified if 1 of the 2 following conditions were met: (1) a robotic
International Classification of Diseases, Ninth Edition (ICD-9) procedure
code accompanied the primary procedure code of interest or (2) text fields
were found when mining the hospital charge master file for each patient
indicating use of the robot. Procedures that involved conversion from
minimally invasive to open or between robotic and VATS approaches
were excluded from the analysis dataset.
For all eligible patients, elements describing hospital cost, surgery time,
length of stay, use of robot, type of thoracic procedure, and indication for
procedure were obtained from the data. Cost analysis (calculation)
reflected the cost of the robotic procedure to the hospital but did not include
acquisition or the annual maintenance fee for the da Vinci robot (Intuitive
Surgical, Inc, Sunnyvale, Calif). The preoperative All Patient Refined
Diagnosis Related Groups (APR-DRG) severity level was used as an index
of comorbidity. The 3M APR-DRG Classification System is a widely
adopted proprietary risk adjustment classification tool that uses
information from routine claims data to produce valid and reliable severity
measurement and risk adjustment scores.13 It is used to account for
differences related to an individual’s severity of illness or risk of mortality
in large datasets. Comorbid conditions that might influence procedure
selection or outcomes of interest, such as the presence of cardiovascular
or pulmonary disease, cancer, or diabetes mellitus, were obtained using
ICD-9 diagnosis codes. Appendix Table 1 provides a detailed list of all
ICD-9 codes for each condition included in the study. Information on socio-
demographic characteristics and health insurance status was also included,
as were descriptors of the care setting, namely census region, urban or rural
setting, teaching hospital status, and facility bed count.ery c March 2014
TABLE 2. Patient demographics—before match
Category
Lobectomy Wedge resection
RATS VATS
P value
RATS VATS
P valueN Percent N Percent N Percent N Percent
Total number 335 100 3818 100 330 100 11,019 100
Age (mean) 66.36 66.27 .8856 61.81 59.56 .0126
Age group .9089 .1606
18-40 y 7 2.09 83 2.17 32 9.7 1443 13.1
41-50 y 25 7.46 243 6.36 28 8.48 1302 11.82
51-60 y 60 17.91 738 19.33 75 22.73 2263 20.54
61-70 y 109 32.54 1288 33.73 98 29.7 2959 26.85
71-80 y 102 30.45 1145 29.99 75 22.73 2359 21.41
>80 y 32 9.55 321 8.41 22 6.67 693 6.29
Gender .4484 .7783
Female 176 52.54 2088 54.69 169 51.21 5451 49.47
Male 159 47.46 1730 45.31 161 48.79 5564 50.49
Unknown 0 0 0 0 0 0 4 0.04
Insurance <.0001 .7399
Government 195 58.21 2490 65.22 186 56.36 5973 54.21
Managed care 124 37.01 977 25.59 103 31.21 3617 32.83
Other 16 4.78 351 9.19 41 12.42 1429 12.97
Race <.0001 .0011
White 240 71.64 3012 78.89 264 80 8021 72.79
African American 14 4.18 327 8.56 21 6.36 1045 9.48
Hispanic 40 11.94 60 1.57 16 4.85 345 3.13
Other 41 12.24 419 10.97 29 8.79 1608 14.59
Health status* .1353 .001
APR-DRG severity level (1, 2) 267 79.7 2905 76.09 273 82.73 8236 74.74
APR-DRG severity level (3, 4) 68 20.3 913 23.91 57 17.27 2783 25.26
Malignancy indication .0093 .0006
No lung cancer 48 14.33 376 9.85 168 50.91 6761 61.36
Primary neoplasm of the lung 266 79.4 3268 85.59 116 35.15 3064 27.81
Metastases other than lung 21 6.27 174 4.56 46 13.94 1194 10.84
Comorbid conditions
Myocardial infarction, acute or old 30 8.96 358 9.38 .7994 30 9.09 825 7.49 .2767
Congestive heart failure 22 6.57 235 6.16 .7641 24 7.27 900 8.17 .5580
Chronic or unspecified heart failure 6 1.79 58 1.52 .6985 3 0.91 287 2.6 .0544
Peripheral vascular disease 30 8.96 396 10.37 .4125 25 7.58 798 7.24 .8178
Dementia 9 2.69 54 1.41 .0678 5 1.52 139 1.26 .6849
Chronic pulmonary disease 171 51.04 1917 50.21 .7694 163 49.39 5649 51.27 .5026
Connective tissue disease 8 2.39 149 3.9 .1634 18 5.45 549 4.98 .6980
Liver disease 18 5.37 184 4.82 .6514 23 6.97 647 5.87 .4043
Chronic viral hepatitis 0 0 33 0.86 .0876 5 1.52 113 1.03 .3876
Renal insufficiency, chronic 22 6.57 270 7.07 .7291 18 5.45 801 7.27 .2094
Diabetes mellitus 82 24.48 770 20.17 .0611 51 15.45 2161 19.61 .0603
RATS, Robot-assisted thoracic surgery; VATS, video-assisted thoracic surgery; APR-DRG, all patient refined diagnosis related group. *APR-DRG severity level was used as an
index of preoperative comorbidity.
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tively and within 30 days postoperatively that included pulmonary
complications were flagged and included in the analysis. These were
further grouped as major or minor complications for analysis. A detailed
list of each event and the corresponding ICD-9 code is found in
Appendix Table 2.Statistical Analysis
The study objective was to use the Premier hospital database to compare
clinical and economic outcomes in patients undergoing lobectomy orThe Journal of Thoracic and Cawedge resection using VATS versus RATS. Outcomes of interest included
adverse events (minor andmajor), hospital costs, length of stay, and surgery
time. Costs were the actual costs incurred by the hospital for all treatments
and services related to the lobectomy and wedge resection and did not
include robotic capital or service contracts.
A quasi-randomization method called propensity scoring was used to
create groups of analyzable patients who were well matched. Propensity
scores were assigned based on likely predictors of the outcome of interest.
Covariates on which to match were selected based on their availability in
the Premier database, as well as their general acceptance as factors associ-
ated with the outcomes of interest. The goal of this propensity-matchingrdiovascular Surgery c Volume 147, Number 3 931
TABLE 3. Hospital demographics based on patient counts
Category
Lobectomy Wedge resection
RATS VATS
P value
RATS VATS
P valueN Percent N Percent N Percent N Percent
Total number 335 100 3818 100 330 100 11,019 100
Census region <.0001 <.0001
Northeast 52 15.52 908 23.78 77 23.33 2858 25.94
West 0 0 603 15.79 22 6.67 1755 15.93
South 253 75.52 1693 44.34 200 60.61 4160 37.75
Midwest 30 8.96 614 16.08 31 9.39 2246 20.38
Location .1851 .0539
Urban 315 94.03 3650 95.6 319 96.67 10,375 94.16
Not urban 20 5.97 168 4.4 11 3.33 644 5.84
Type <.0001 <.0001
Teaching 292 87.16 2132 55.84 281 85.15 5744 52.13
Nonteaching 43 12.84 1686 44.16 49 14.85 5275 47.87
Bed count .0023 .0585
<50 0 0 0 0 0 0 7 0.06
51–100 0 0 15 0.39 0 0 40 0.36
101–200 1 0.3 141 3.69 6 1.82 515 4.67
>200 334 99.7 3662 95.91 324 98.18 10,457 94.9
RATS, Robot-assisted thoracic surgery; VATS, video-assisted thoracic surgery.
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tion via RATS or VATS procedures, who shared like propensities based on
the matching variables. An SAS macro from the Mayo Clinic used nearest-
neighbor matching on the estimated propensity scores to choose matches
for the patients who had a RATS procedure.14 Propensity scores were
calculated for receipt of robotic procedures for each patient included in
the analysis based on a nonparsimonious multivariable logistic regression
model. Patients were matched on the following characteristics: severity
group, age, gender, race, region, size of facility, teaching facility (yes/
no), location of facility, insurance group, malignancy status, chronic pul-
monary disease, chronic viral hepatitis, connective tissue disease, conges-
tive heart failure, diabetes mellitus, liver disease, myocardial infarction,
acute or old, other chronic or unspecified heart failure, peripheral vascular
disease, and chronic renal insufficiency. The robotic and nonrobotic pa-
tients were randomly ordered and a nonrobotic patient with a propensity
score closest to the first robotic patient was chosen. Assessment of residual
bias was conducted by evaluating the differences in the distribution of pa-
tient characteristics before and after matching.
To assess the extent to which the propensity matching reduced
confounders, the distribution of several variables before and after matching
were compared, including age, gender, race, insurance type, health status,
malignancy indication, region, location, facility type, facility size, and
comorbid conditions among the patients in the cohorts. Group comparisons
were made using c2 tests. Least square means were used to test for
differences between the matched cohorts on the 3 continuous variables
of interest: hospital cost, surgery time, and length of stay. Logistic
regression models were used to test for significant differences between
the 2 groups and to generate odds ratios on the following categories of
adverse events/complications: major and minor. To further assess any
residual bias that may occur because only a few hospitals represent most
of the robotic procedures in the sample, sensitivity analysis was conducted
by running multiple regression models on 1 of the hospitals in which most
of the robotic procedures were performed and a nonrobotic hospital
meeting the same hospital characteristics. Ordinary least squares
regression models were run for hospital costs and logistic regression
models were run for adverse events, both major and minor. Analyses
were performed using SAS Version 9.2 (SAS Institute Inc., Cary, NC).932 The Journal of Thoracic and Cardiovascular SurgRESULTS
A total of 15,502 patient records from 305 hospitals were
analyzed. The patient attrition process is shown in Table 1.
Ninety-six percent of these thoracic procedures were
traditional VATS (n ¼ 14,837); lung resection was
performed with RATS in 665 procedures, 4% of the total.
In the robotic group, 335 lobectomies and 330 wedge
resections were performed.
Before matching, patients undergoing RATS lobectomy
had similar distributions for age, gender, and health status.
Those undergoing RATS resection had similar distributions
for age, gender, and insurance type compared with those un-
dergoing VATS lung resection (Table 2). Furthermore, few
differences in comorbidities were noted between robot and
nonrobot groups. Characteristics of the hospitals showed
notable differences for region, teaching versus nonteaching,
and bed count. For teaching versus nonteaching and bed
count, most of the robotic procedures were performed in
teaching hospitals (292 of 335 lobectomies, 281 of 330
wedge resections) with more than 200 beds (334 of 335 lo-
bectomies, 324 of 330 wedge resections), compared with
nonrobotic procedures, with almost half coming from
nonteaching hospitals (44% lobectomy, 48% wedge resec-
tion) with greater variation in bed size (Table 3).
To balance cohorts and mitigate the possibility of
confounders and the large discrepancy in sample size
between robotic and nonrobotic procedures, patients were
matched using a propensity score, as described earlier, on
certain demographic and hospital characteristics. After
matching, a total of 1240 patients remained; 590
lobectomies and 650 wedge resections in each groupery c March 2014
TABLE 4. Patient demographics—matched cohorts
Category
Lobectomy Wedge resection
RATS VATS
P value
RATS VATS
P valueN Percent N Percent N Percent N Percent
Total number 295 100 295 100 325 100 325 100
Age (mean) 66.43 66.54 .9112 61.74 61.50 .8403
Age group .9596 .9307
18–40 y 7 2.37 5 1.69 32 9.85 34 10.46
41-50 y 21 7.12 18 6.1 28 8.62 32 9.85
51-60 y 51 17.29 58 19.66 74 22.77 63 19.38
61-70 y 99 33.56 98 33.22 95 29.23 98 30.15
71-80 y 88 29.83 88 29.83 75 23.08 78 24
>80 y 29 9.83 28 9.49 21 6.46 20 6.15
Gender .4574 .0698
Female 154 52.2 163 55.25 167 51.38 190 58.46
Male 141 47.8 132 44.75 158 48.62 135 41.54
Unknown
Insurance .6862 .7658
Government 173 58.64 180 61.02 183 56.31 174 53.54
Managed care 106 35.93 103 34.92 101 31.08 106 32.62
Other 16 5.42 12 4.07 41 12.62 45 13.85
Race .4626 .9712
White 235 79.66 249 84.41 264 81.23 264 81.23
African American 14 4.75 11 3.73 21 6.46 21 6.46
Hispanic 7 2.37 7 2.37 11 3.38 13 4
Other 39 13.22 28 9.49 29 8.92 27 8.31
Health status* .7597 .1921
APR-DRG severity level (1, 2) 233 78.98 236 80 269 82.77 281 86.46
APR-DRG severity level (3, 4) 62 21.02 59 20 56 17.23 44 13.54
Malignancy indication .9706 .5428
No lung cancer 40 13.56 38 12.88 167 51.38 169 52
Primary neoplasm of the lung 238 80.68 240 81.36 113 34.77 120 36.92
Metastases other than lung 17 5.76 17 5.76 45 13.85 36 11.08
Census region <.0001 .9672
Northeast 50 16.95 94 31.86 77 23.69 82 25.23
West 0 0 23 7.8 22 6.77 23 7.08
South 215 72.88 123 41.69 195 60 190 58.46
Midwest 30 10.17 55 18.64 31 9.54 30 9.23
Location .4915 .2464
Urban 275 93.22 279 94.58 314 96.62 308 94.77
Not urban 20 6.78 16 5.42 11 3.38 17 5.23
Type .3974 1.0000
Teaching 252 85.42 259 87.8 276 84.92 276 84.92
Nonteaching 43 14.58 36 12.2 49 15.08 49 15.08
Bed count .5627 .0117
<50 0 0 0 0
51–100 0 0 0 0 0 0 1 0.31
101–200 1 0.34 2 0.68 6 1.85 20 6.15
>200 294 99.66 293 99.32 319 98.15 304 93.54
Comorbid conditions
Myocardial infarction, acute or old 26 8.81 24 8.14 .7675 29 8.92 28 8.62 .8897
Congestive heart failure 21 7.12 16 5.42 .3959 22 6.77 20 6.15 .7497
Chronic or unspecified heart failure 6 2.03 8 2.71 .5885 3 0.92 3 0.92 1.0000
Peripheral vascular disease 25 8.47 27 9.15 .7715 25 7.69 24 7.38 .8819
Dementia 8 2.71 3 1.02 .1281 5 1.54 3 0.92 .4768
Chronic pulmonary disease 148 50.17 153 51.86 .6805 161 49.54 165 50.77 .7537
(Continued)
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TABLE 4. Continued
Category
Lobectomy Wedge resection
RATS VATS
P value
RATS VATS
P valueN Percent N Percent N Percent N Percent
Connective tissue disease 8 2.71 8 2.71 1.0000 18 5.54 17 5.23 .8620
Liver disease 16 5.42 9 3.05 .1525 22 6.77 15 4.62 .2360
Chronic viral hepatitis 0 0 2 0.68 .1566 5 1.54 3 0.92 .4768
Renal insufficiency, chronic 21 7.12 10 3.39 .0424 18 5.54 17 5.23 .8620
Diabetes mellitus 68 23.05 60 20.34 .4242 50 15.38 52 16 .8292
RATS, Robot-assisted thoracic surgery; VATS, video-assisted thoracic surgery; APR-DRG, all patient refined diagnosis related group. *APR-DRG severity level was used as an
index of preoperative comorbidity.
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where robotic procedures were being performed. Patient
characteristics, comorbid conditions, and hospital
characteristics after matching are represented in Table 4.
After matching, patients were balanced with respect
to demographics, comorbid conditions, and hospital charac-
teristics, with the exception of region for the lobectomy
cohort and bed count for the wedge resection cohort.
After matching, cohorts were tested for differences in
average hospital costs, operating room time, and length of
stay (Table 5). The average cost of inpatient procedures
with/without robotic assistance was $25,040.70 versus
$20,476.58 (P ¼ .0001) for lobectomies and $19,592.42
versus $16,600.13 (P ¼ .0001) for wedge resections,
respectively. Operating room times were longer, although
not statistically different for robotic lobectomy (4.49 vs
4.23 hours; P ¼ .0959). Operating room times were
increased for robotic wedge resection versus nonrobotic
wedge resection (3.26 vs 2.86 hours; P ¼ .0003). Average
length of stay of both cohorts was not statistically different
for lobectomy (6.07 vs 5.83 days; P ¼ .6131) and wedge
resection (5.23 vs 5.38 days; P ¼ .7188).
Adverse events occurring in the postoperative period, up
to 30 days after discharge, were tabulated and grouped intoTABLE 5. Length of stay, hospital costs, and surgery time after matching
Lobectomy
RATS VATS
Length of stay (d)
Median 4 4
Mean 6.07 5.83
SD 6.44 5.03
Total hospital costs ($)
Median 21,833.34 18,080.11
Mean 25,040.70 20,476.58
SD 13,164.01 10,977.67
Operating room time (h)
Median 4.25 4
Mean 4.49 4.23
SD 1.98 1.73
RATS, Robot-assisted thoracic surgery; VATS, video-assisted thoracic surgery; SD, standa
934 The Journal of Thoracic and Cardiovascular Surgmajor and minor. Complications rates between robotic and
nonrobotic surgery cohorts, regardless of whether they were
examined within a perioperative 30-day period or only
within the original perioperative hospital stay (Table 6)
were reported. The odds of an event occurring were not
significantly different for major and minor events in either
time period for lobectomy or wedge resection (Table 7).
Sensitivity Analysis
In the propensity model, the following hospital character-
istics were adjusted: location (urban vs rural), region,
teaching status, and bed size. However, more hospitals
contributed to our sample of nonrobotic procedures than
robotic procedures. Of the 132 hospitals in our sample,
only 40 had robotic procedures. Therefore, to further assess
any residual bias that may occur because only a few
hospitals represented most of the robotic procedures in
the sample, the 1 hospital in which 126 lobectomies and
71 wedge resections were performed was matched to a non-
robotic hospital meeting the same hospital characteristics:
southern, urban, teaching with a bed count of 500. Only
the patients from these 2 hospitals were analyzed. Results
of the ordinary least squares cost model revealed signifi-
cantly higher differences in costs for RATS lobectomyWedge resection
P value RATS VATS P value
4 4
.6131 5.23 5.38 0.7188
5.18 5.27
17,341.33 13,640.52
<.0001 19,592.42 16,600.13 .0001
9,293.64 10,367.82
2.93 2.5
.0959 3.26 2.86 .0003
1.41 1.31
rd deviation.
ery c March 2014
TABLE 6. Adverse events among matched data by analysis groups
Category
Lobectomy Wedge resection
RATS VATS RATS VATS
During During or after During During or after During During or after During During or after
N Percent N Percent N Percent N Percent N Percent N Percent N Percent N Percent
Total number 295 100 295 100 295 100 295 100 325 100 325 100 325 100 325 100
Any major event 40 13.56 50 16.95 50 16.95 56 18.98 53 16.31 71 21.85 41 12.62 51 15.69
Acute respiratory failure 16 5.42 18 6.1 20 6.78 22 7.46 21 6.46 32 9.85 20 6.15 22 6.77
Empyema 1 0.34 2 0.68 1 0.34 2 0.68 1 0.31 3 0.92 4 1.23 4 1.23
Bronchopleural fistula 5 1.69 5 1.69 2 0.68 3 1.02 3 0.92 3 0.92 1 0.31 1 0.31
Pneumonia 18 6.1 25 8.47 27 9.15 29 9.83 28 8.62 33 10.15 16 4.92 24 7.38
Any minor event 100 33.90 109 36.95 101 34.24 113 38.31 100 30.77 108 33.23 106 32.62 114 35.08
Air leak and other
pneumothorax
70 23.73 75 25.42 65 22.03 70 23.73 78 24 80 24.62 78 24 81 24.92
Atelectasis/pulmonary
collapse
30 10.17 33 11.19 36 12.2 43 14.58 19 5.85 25 7.69 24 7.38 28 8.62
Cellulitis 0 0 1 0.34 0 0 0 0 0 0 0 0 0 0 1 0.31
Chylothorax 1 0.34 1 0.34 3 1.02 3 1.02
Spontaneous tension
pneumothorax
0 0 0 0 1 0.34 2 0.68 3 0.92 3 0.92 4 1.23 4 1.23
RATS, Robot-assisted thoracic surgery; VATS, video-assisted thoracic surgery; SD, standard deviation.
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wedge resection versus VATS wedge resection ($27,969
vs $17,887). Regarding adverse events, results were
confirmatory for major events in both lobectomy and wedge
resection with no statistical differences. Regarding minor
events, there were no differences for patients undergoing
wedge resection. However, there was a significant differ-
ence for lobectomies. Patients who underwent lobectomy
with the robot were 4.24 (odds ratio) times more likely to
have a minor event then their nonrobotic counterparts
(P<.0001).
DISCUSSION
Based on our matched cohorts, there seems to be no
differences between robot-assisted lobectomy and wedge
resection procedures when considering intraoperative and
postoperative complications. After matching and creating
2 balanced cohorts, robot-assisted procedures were associ-
ated with higher hospital costs, with an average incremental
cost per procedure of $4565 for lobectomy and $2992 for
wedge resection. Robot-assisted wedge procedures were
also associated with longer operating room times.TABLE 7. Adverse events after matching
Lobectomy
Odds ratio estimate Lower CI Upper CI P valu
Original hospital stay or within 30 d of follow-up
Major 0.864 0.537 1.389 .5458
Minor 1.015 0.722 1.427 .9308
Original hospital stay only
Major 0.789 0.473 1.316 .3645
Minor 1.032 0.728 1.462 .8589
CI, Confidence interval.
The Journal of Thoracic and CaThe findings related to higher hospital costs associated
with robotic surgery are consistent with similar studies in
the literature evaluating minimally invasive surgical
procedures15,16; robotic surgery is consistently more
expensive.
Another important consideration is that the costs associa-
ted with robotic surgery in these studies do not account for
substantial acquisition costs for the robot. The robotic unit
costs between $1 million and $2.5 million, and is associated
with annual maintenance costs of $100,000 to $180,000.17
The combination of limited high-quality clinical evidence
comparing traditional VATS and RATS lobectomy and
wedge resection to date and relatively high costs raises
questions about the cost-effectiveness of this technology.
In addition, robotic surgery ideally requires a dedicated
operating team and an additional surgeon at the table,
who are not generally required for standard VATS
procedures. This cost is difficult to assess but certainly
needs to be considered.
Important strengths of this analysis included the prospec-
tively developed protocol that directed the analysis, the
quasi-randomization propensity scoring methodology thatWedge resection
e Odds ratio estimate Lower CI Upper CI P value
1.24 0.807 1.905 .3265
0.971 0.695 1.357 .8647
1.224 0.763 1.963 .4013
0.927 0.659 1.304 .6639
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tation of US hospitals included in the sample, and the fact
that these data are relatively recent and represent a national
setting. This study also had some noteworthy limitations.
Because the data were mined from a hospital administrative
database used for billing purposes, certain data points could
not be captured or could not be clearly identified. Examples
include patient body mass index and patient behavior such
as smoking habits. An analysis of pain scores, quality of
life, morbidity, and time to return to work would be
interesting contributions to the literature, but these data
are not available in the database used in this analysis.
This analysis was limited to patients who underwent
VATS or RATS procedures only, and excluded those
procedures that were converted from RATS to VATS or to
open thoracotomy. Furthermore, data regarding the
precision of robotic versus nonrobotic procedures,
including surgical margins and adequacy of lymph node
dissection, could not be evaluated. The dataset provides
operating room time and is not suited to further exploration
regarding time allotted to set-up, bronchoscopy, take down
of adhesions, preresection examination or other subcate-
gories. The analysis was limited to a 30-day perioperative
period, which limits analysis related to long-term survival
or potential long-term complications. However, these
limitations are inherent to the data source and could be
rationalized to affect both cohorts similarly; therefore, the
risk of bias in 1 cohort is lessened. The surgeon and
institutional learning curve for using robotic technology
could not be evaluated. Because robotic lung surgery is a
relatively new procedure, there may be future potential
efficiencies in both cost and time related to increasing
familiarity with this technology.
CONCLUSIONS
This study represents the most up-to-date and expansive
analysis of cost and effectiveness outcomes associated with
RATS and VATS procedures in a national setting. These
findings reveal little clinical differences in perioperative
adverse events. Coupled with the increased cost of the
robot per case and increased operative times for robotic
lobectomy and wedge resections, results suggest that
further consideration is warranted before using this
technology when standard VATS seems to provide better
results. Future studies that evaluate cost relative to
robotic-assisted case volume and prospective randomized936 The Journal of Thoracic and Cardiovascular Surgcontrolled studies focusing on comparative effectiveness
between traditional and robotic-assisted thoracic proce-
dures are needed.References
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APPENDIX TABLE 1. Comorbid conditions
Condition ICD-9 code
Myocardial infarction,
acute or old
410.xx, 412
Congestive heart failure 428.0
Other chronic or unspecified
heart failure
428.20, 428.22, 428.30,
428.32, 428.40, 428.42, 428.9
Peripheral vascular disease 440.xx, 443.8x, 443.9
Dementia 290.xx, 294.xx, 331.0, 331.11,
331.19, 331.2, 331.7, 331.82
Chronic pulmonary disease 490.xx-494.xx, 495.x, 496, 500-505
Connective tissue disease 710.xx, 714.xx
Liver disease 571.x, 572.x, 573.xx
Chronic viral hepatitis 070.22-070.23, 070.32-070.33,
070.44, 070.54
Renal insufficiency, chronic 585.xx
Diabetes mellitus 249.xx, 250.xx
Hemiplegia 342.xx
Due to cerebral palsy 343.1, 343.4
Due to previous
cardiovascular accident
438.2x
ICD, International Classification of Diseases.
APPENDIXTABLE 2. Postoperative procedure-specific complications
Category Pulmonary ICD-9 code
Major Acute respiratory failure 518.81, 518.84 , 518.5
Major Empyema 510.9
Major Bronchopleural fistula 510.0
Major Pneumonia 480.x to 486, 507.0
Minor Spontaneous tension
pneumothorax
512.0
Minor Atelectasis/pulmonary
collapse
518.0
Minor Air leak and other
pneumothorax
512.1, 512.8
Minor Chylothorax 457.8
Minor Cellulitis 682.2
ICD, International Classification of Diseases.
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